China Officials Said To Order Probes By Lilly, AstraZeneca, Novo Nordisk
This article was originally published in PharmAsia News
Executive Summary
China drug authorities may be finished with the GlaxoSmithKline case, but several other global drug makers face continuing investigations, the latest reportedly being of Eli Lilly by Hangzhou health officials.